Regulated information – Inside information
November 12, 2019 - 10:00 PM CET
Breda, the Netherlands / Ghent,
Belgium – argenx (Euronext & Nasdaq: ARGX) a
clinical-stage biotechnology company developing a deep pipeline of
differentiated antibody-based therapies for the treatment of severe
autoimmune diseases and cancer, announced today the closing of its
global offering of an aggregate of 4,600,000 ordinary shares
(including in the form of American Depositary Shares (ADSs)), which
includes the full exercise of the underwriters’ option to purchase
600,000 additional ADSs. The global offering consisted of (i) a
public offering of 2,010,057 ADSs in the United States and certain
other countries outside the European Economic Area (EEA) at a price
to the public of $121.00 and (ii) a concurrent private placement of
2,589,943 of ordinary shares in the EEA at an offering price of
€109.18. The gross proceeds from the global offering were
approximately $557 million (approximately €502 million).
Morgan Stanley, Cowen, BofA Securities and
Evercore acted as joint bookrunning managers for the offering.
Kempen acted as lead manager for the offering and Wolfe Capital
Markets and Advisory acted as co-manager.
The securities were offered pursuant to an
automatically effective shelf registration statement that was
previously filed with the Securities and Exchange Commission (SEC).
A preliminary prospectus supplement relating to the securities was
filed with the SEC on November 6, 2019 and a final prospectus
supplement relating to the securities was filed with the SEC on
November 8, 2019 and are available on the SEC’s website at
www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus relating to the global offering may be
obtained for free from Morgan Stanley & Co. LLC, 180 Varick
Street, 2nd Floor, New York, New York 10014, United States,
Attention: Prospectus Department; from Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com, or by telephone at (833)
297-2926; BofA Securities, NC1-004-03-43, 200 North College Street,
3rd floor, Charlotte, North Carolina 28255-0001, Attn: Prospectus
Department, or by email at dg.prospectus_requests@baml.com; or
Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East
52nd Street, 36th Floor, New York, NY 10055, or by telephone at
(888) 474-0200.
In addition, argenx announced today the listing of
and the commencement of dealings in its 4,600,000 new ordinary
shares (including those underlying the ADSs) on the regulated
market of Euronext Brussels, effective today, November 12,
2019.
This press release is for information purposes
only and does not constitute, and should not be construed as, an
offer to sell or the solicitation of an offer to buy or subscribe
to any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale is not
permitted or to any person or entity to whom it is unlawful to make
such offer, solicitation or sale. Reference is also made to the
restrictions set out in “Important information” below. This press
release is not for publication or distribution, directly or
indirectly, in or into any state or jurisdiction into which doing
so would be unlawful or where a prior registration or approval is
required for such purpose.
About argenxargenx is a
clinical-stage biotechnology company developing a deep pipeline of
differentiated antibody-based therapies for the treatment of severe
auto-immune diseases and cancer. The company is focused on
developing product candidates with the potential to be either
first-in-class against novel targets or best-in-class against
known, but complex, targets in order to treat diseases with a
significant unmet medical need. argenx’s ability to execute on this
focus is enabled by its suite of differentiated technologies. The
SIMPLE AntibodyTM Platform, based on the powerful llama immune
system, allows argenx to exploit novel and complex targets, and its
three complementary Fc engineering technologies are designed to
expand the therapeutic index of its product candidates.
For further information, please
contact: Joke Comijn, Director Corporate Communications
& Investor Relations (EU)+32 (0)477 77 29 44+32 (0)9 310 34
19info@argenx.com
Beth DelGiacco, Vice President, Investor
Relations (US)+1 518 424 4980bdelgiacco@argenx.com
Forward-looking StatementsThe
contents of this announcement include statements that are, or may
be deemed to be, “forward-looking statements.” These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “believes,”
“estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” or
“should.” By their nature, forward-looking statements involve
risks and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. argenx’s actual results may differ materially from
those predicted by the forward-looking statements as a result of
various important factors, including argenx’s expectations
regarding the inherent uncertainties associated with competitive
developments, preclinical study and clinical trial and product
development activities and regulatory approval requirements;
argenx’s reliance on collaborations with third parties; estimating
the commercial potential of argenx’s product candidates; argenx’s
ability to obtain and maintain protection of intellectual property
for its technologies and drugs; argenx’s limited operating history;
and argenx’s ability to obtain additional funding for operations
and to complete the development and commercialization of its
product candidates. A further list and description of these risks,
uncertainties and other risks can be found in argenx’s U.S.
Securities and Exchange Commission (SEC) filings and reports,
including in argenx’s most recent annual report on Form 20-F filed
with the SEC as well as subsequent filings and reports filed by
argenx with the SEC. Given these uncertainties, the reader is
advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the
date of publication of this document. argenx undertakes no
obligation to publicly update or revise the information in this
press release, including any forward-looking statements, except as
may be required by law.
Important informationThe
prospectus supplement does not constitute a prospectus within the
meaning of the Prospectus Regulation and has not been approved by
the Dutch Authority for the Financial Markets (Stichting Autoriteit
Financiële Markten) or the Belgian Financial Services and Markets
Authority (Autoriteit Financiële Diensten en Markten) or any other
European Supervisory Authority.
No public offering was made and no one has taken
any action that would, or was intended to, permit a public offering
in any country or jurisdiction, other than the United States, where
any such action is required, including in the European Economic
Area. In the European Economic Area, the transaction to which this
press release relates will only be available to, and will be
engaged in only with, qualified investors within the meaning of
Directive 2003/71/EC (together with any applicable implementing
measures in the relevant member state of the European Economic Area
and as amended, including by Directive 2010/73/EU, to the extent
implemented in the relevant member state).
European Economic Area:No
action has been taken to offer the shares to a retail investor
established in the European Economic Area as part of the global
offering. For the purposes of this paragraph:
- The expression
"retail investor" means
a person who is one (or more) of:
- a retail client as defined
in point (11) of Article 4(1) of Directive 2014/65/EU (as amended,
“MiFID II”); or
- a customer within the meaning of
Directive 2016/97/EU, as amended, where that customer would not
qualify as a professional client as defined in point (10) of
Article 4(1) of MiFID II; or
- not a “qualified investor” as defined
in the Prospectus Regulation; and
- the expression
“offer” means any communication in any form and by
any means of sufficient information on the terms of the offer and
securities to be offered so as to enable an investor to decide to
purchase or subscribe these securities.
In addition, in the United Kingdom, the
transaction to which this press release relates will only be
available to, and will be engaged in only with, investment
professionals falling within Article 19(5) of the Financial
Services and Markets Act (Financial Promotion) Order 2005, as
amended (the Order), persons falling within Article 49(2)(a) to (d)
of the Order, and other persons to whom this announcement may
lawfully be communicated (all such persons together being referred
to as "relevant persons"). The securities referred to herein are
only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be
engaged in only with relevant persons. Any person who is not a
relevant person should not act or rely on this communication or any
of its contents.
This press release is not an approved prospectus
by the Financial Services Authority or by any other regulatory
authority in the United Kingdom within the meaning of Section 85 of
the Order.
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Sep 2023 to Sep 2024